Brain Penetrant LRRK2 Inhibitor-Reference-Cited by-同舟云学术

Brain Penetrant LRRK2 Inhibitor

Published:2012-06-22 Issue:8 Volume:3 Page:658-662
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Choi Hwan Geun¹²,Zhang Jinwei³,Deng Xianming¹²,Hatcher John M.¹²,Patricelli Matthew P.⁴,Zhao Zheng⁵,Alessi Dario R.³,Gray Nathanael S.¹²

Affiliation:

1. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States

2. Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 250 Longwood Avenue, SGM 628, Boston, Massachusetts 02115, United States

3. MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, United Kingdom

4. ActivX Biosciences, 11025 North Torrey Pines Road, La Jolla, California 92037, United States

5. High Magnetic Field Laboratory, Chinese Academy of Science, P.O. Box 1110, Hefei, Anhui, 230031, People's Republic of China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ml300123a

Reference23 articles.

1. Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease

2. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

3. On the Road to Leucine-Rich Repeat Kinase 2 Signalling: Evidence from Cellular and in vivo Studies

4. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

5. LRRK2 and Parkinson Disease

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging perspectives on precision therapy for Parkinson’s disease: multidimensional evidence leading to a new breakthrough in personalized medicine;Frontiers in Aging Neuroscience;2024-07-04

2. Swimming short fibrous nasal drops achieving intraventricular administration;Science Bulletin;2024-05

3. Concurrent Optimizations of Efficacy and Blood–Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson’s Disease Therapeutics;Journal of Medicinal Chemistry;2024-04-29

4. Molecular dynamic investigation for Roco4 kinase inhibitor as treatment options for parkinsonism;Journal of Molecular Modeling;2024-04-16

5. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson’s disease;Bioorganic Chemistry;2024-02